EDP-494 / Enanta Pharma - LARVOL DELTA

Enanta Pharmaceuticals announces highlights of business overview and update on its research and development programs to be presented at the 35th Annual J.P. Morgan Healthcare Conference (Enanta Press Release) - "AbbVie has announced that it is planning for the commercial launch of G/P to begin in the U.S. in 2017...Enanta now believes that G/P has the best and most timely potential for Enanta to participate in the treatment of those HCV patients who have failed on other treatment regimens. Therefore, Enanta has decided to stop further development of EDP-494..."

Anticipated launch US • Discontinued • Hepatitis C Virus

EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients (clinicaltrials.gov) - P1; N=100; Completed; Sponsor: Enanta Pharmaceuticals; Recruiting ➔ Completed

Trial completion • Biosimilar • Hepatitis C Virus • Immunology